About tafasitamab
CD19-directed monoclonal antibody
Used for
- With lenalidomide, treats adults with relapsed or refractory diffuse large B-cell lymphoma who are not candidates for autologous stem-cell transplant.
Usual adult dose
12 mg/kg by intravenous infusion on days 1, 4, 8, 15, and 22 of cycles 1–3; days 1 and 15 of cycles 4–6; then day 1 of each later cycle. Each cycle lasts 28 days.
Common side effects
- Infusion reactions
- Low blood-cell counts, including neutropenia and thrombocytopenia
- Infections
- Diarrhea, rash, or fatigue
Important warnings
- Serious or fatal infections and low blood-cell counts can occur.
- Infusion reactions may be severe; monitoring and premedication are required.
- May cause fetal harm; effective contraception is advised during treatment and for three months afterward.
- Treatment can interfere with certain blood compatibility tests; notify the blood bank before transfusion.
Pregnancy
May cause fetal harm. Human pregnancy data are limited; avoid pregnancy during treatment and for three months after the last dose.
Breastfeeding
It is not known whether tafasitamab passes into breast milk. Breastfeeding is not recommended during treatment or for three months afterward.
Interactions
- Lenalidomide is used with tafasitamab for this indication.
- No specific clinically important drug interactions are established.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.